Showing 1711-1720 of 5643 results for "".
- Notal Vision: Clinical Trials Demonstrate Value of Home OCThttps://modernod.com/news/notal-vision-clinical-trials-demonstrate-value-of-home-oct/2481429/Notal Vision reported that the latest data on its investigational home-based optical coherence tomography (OCT) and how the service can be used to manage wet age-related macular degeneration (AMD) were recently presented at the Angiogenesis, Exudation, and Degeneration and Macula Society 202
- Visionary Optics New Scleral Lens Design, Europa Tangenthttps://modernod.com/news/visionary-optics-new-scleral-lens-design-europa-tangent/2481375/Visionary Optics announced the launch of Europa Tangent, a scleral lens that combines a customizable design with a streamlined fitting process. The lens design is based on clinical experience and analysis of over 10,000 fittings driven by profilometry data and Visionary Optics’ sc
- Novartis Acquires Kedalion Therapeutics and its Ocular Delivery Platformhttps://modernod.com/news/novartis-acquires-kedalion-therapeutics-and-its-ocular-delivery-platform/2480952/Novartis announced that it has acquired Kedalion Therapeutics and its AcuStream technology, a device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye.1,2 Terms of the deal were
- Efficacy of Notal Vision Home OCT Demonstrated by a Series of Scientific and Clinical Workhttps://modernod.com/news/efficacy-of-notal-vision-home-oct-demonstrated-by-a-series-of-scientific-and-clinical-work/2480942/Notal Vision reported that scientific and clinical publications and presentations demonstrate the feasibility and efficacy of their patient-operated, home-based optical coherence tomography (OCT) device. As part of a comprehensive remote monitoring service, which includes a monitoring center and
- Nova Eye Medical Launches Next Generation Canaloplasty Device for Glaucoma, iTrack Advancehttps://modernod.com/news/nova-eye-medical-launches-next-generation-canaloplasty-device-for-glaucoma-itrack-advance/2480774/Nova Eye Medical announced the launch of its next generation canaloplasty device, iTrack Advance, in select markets in Europe and the Asia Pacific. The iTrack Advance features the proprietary illuminated fiber optic tip of the original iTrack device, which all
- Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Nonclinical Developmenthttps://modernod.com/news/nicox-appoints-doug-hubatsch-as-new-chief-scientific-officer-to-lead-clinical-and-nonclinical-development/2480509/Nicox SA announced the appointment of Doug Hubatsch to lead all of the company’s nonclinical and clinical development activities. As Chief Scientific Officer, Mr. Hubatsch will be responsible for setting the research and development st
- Amydis Receives NIH Grant to Develop a Novel Tau Retinal Tracer for Alzheimer’s Diseases and Other Tauopathieshttps://modernod.com/news/amydis-receives-nih-grant-award-to-develop-a-novel-tau-retinal-tracer-for-alzheimers-diseases-and-other-tauopathies/2479481/Amydis announced a new phase 1 grant award from the National Institute of Aging at the National Institutes of Health (NIH) to support the development of a novel small-molecule retinal tracer targeting the biomarker tau for the detection and diagnosis of Alzheimer’s disease and other tauopathies.<
- Noveome Biotherapeutics Announces Preliminary Results of its Phase 1 Trial Evaluating Intranasal Delivery of ST266 In Glaucoma Suspect Patientshttps://modernod.com/news/noveome-biotherapeutics-announces-preliminary-results-of-its-phase-1-trial-evaluating-intranasal-delivery-of-st266-in-glaucoma-suspect-patients/2479275/Noveome Biotherapeutics announced preliminary results of a phase 1 open label clinical trial to establish the safety of ST266 when delivered intranasally in glaucoma suspect patients. The trial was conducted at the University of Pennsylvania by Ahmara Ross, MD, PhD, and Kenneth Shindler, MD, PhD,
- Novartis Terminates Three Trials of Beovu Despite Meeting Primary Endpoint of MERLIN Trialhttps://modernod.com/news/novartis-terminates-three-trials-of-beovu-despite-meeting-primary-endpoint/2479246/Novartis reported that Beovu met its primary endpoint in the phase 3 MERLIN trial, but decided to terminate the study due to higher rates of intraocular inflammation with frequent dosing intervals. Novartis reported the first interpretable year 1 results of the MERLIN trial, a 2-year study
- Novartis’ Sandoz Unit Confirms Late-Stage Clinical Development Plans for Proposed Biosimilar Aflibercepthttps://modernod.com/news/novartis-sandoz-unit-confirms-late-stage-clinical-development-plans-for-proposed-biosimilar-aflibercept/2479166/Sandoz, a division of Novartis, announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical phase 3 confirmatory efficacy and safety study, shortly.1 Aflibercept (